2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
December 8th 2016
According to the results of the phase III StaMINA trial evaluating posttransplant therapy in multiple myeloma, a second a round of chemotherapy or stem cell transplant does not improve progression-free survival or overall survival compared with the current standard course of treatment alone.
December 7th 2016
An FDA-approved blood cancer drug has demonstrated encouraging findings, including an overall response rate of 67%, in treatment of patients with chronic graft-versus-host-disease that was not resolved by corticosteroids.
July 29th 2016
Treatment with anthracyclines was proven to be beneficial for patients with high-risk, HER2-negative, early-stage breast cancer, according to a joint analysis of the Anthracyclines in Early Breast Cancer (ABC) trials.
July 10th 2016
Phase III results of the KRISTINE trial demonstrated that patients with HER2-positive early breast cancer had a significantly higher pathological complete response rate when they received the neoadjuvant regimen of docetaxel, carboplatin, and trastuzumab plus pertuzumab versus trastuzumab emtansine plus pertuzumab.